Acetazolamide
Glaucoma
We offer no GRADED recommendations regarding patient suitability, indication suitability or the suitability, safety or efficacy of any dosing protocol.
Dosing Suggestion(s)
Glaucoma: 4-10 mg/kg, PO, q8-12h (Whilst intraocular pressure is elevated). It is used in rabbits with glaucoma and as a major species extrapolation (MSE) (Loftsson et al., 1994).
Therapeutics
About Acetazolamide
Acetazolamide is a first-generation carbonic anhydrase inhibitor (CAI) with both diuretic and anti-glaucoma effects (Farzam and Abdullah, 2022).
Ocular effects: Within the eye, CAIs decrease the formation of aqueous humor and reduce intraocular pressure (IOP) (Farzam and Abdullah, 2022).
Diuresis: Acetazolamide increases tubular secretion of bicarbonate alongside sodium and potassium cations and promotes alkaline diuresis (Farzam and Abdullah, 2022).
Evidence Base
Farzam, K., Abdullah, M., 2022. Acetazolamide, in: StatPearls. StatPearls Publishing, Treasure Island (FL).
Kimoto, H., Ohno, T., Takashima, S., Hirano, S., Ozaki, T., 1995. The effect of acetazolamide and carbon dioxide on cerebral hemodynamic changes on near-infrared spectroscopy in young rabbits. Brain Dev 17, 261–263. https://doi.org/10.1016/0387-7604(95)00046-e
Loftsson, T., Frithriksdóttir, H., Stefánsson, E., Thórisdóttir, S., Guthmundsson, O., Sigthórsson, T., 1994. Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits. J Pharm Pharmacol 46, 503–504. https://doi.org/10.1111/j.2042-7158.1994.tb03835.x